Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine - Contacts and Locations

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

This study has been completed.

Study NCT00000635. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000635

Locations


United States, Alabama
	Univ of Alabama at Birmingham
	Birmingham, Alabama, United States, 35294

United States, Colorado
	Univ of Colorado Health Sciences Ctr
	Denver, Colorado, United States, 80262

United States, Maryland
	Johns Hopkins Hosp
	Baltimore, Maryland, United States, 21287

United States, New York
	SUNY - Stony Brook
	Stony Brook, New York, United States, 117948153
	Bellevue Hosp / New York Univ Med Ctr
	New York, New York, United States, 10016
	Saint Luke's - Roosevelt Hosp Ctr
	New York, New York, United States, 10025

United States, South Carolina
	Julio Arroyo
	West Columbia, South Carolina, United States, 29169

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Glaxo Wellcome

Investigators


Study Chair:	Kessler H A